Opaleye Management Inc. Cardiff Oncology, Inc. Transaction History

Opaleye Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	SELL	$5.01 - $7.58 $2.32 Million - $3.51 Million	-463,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $751,450 - $1.13 Million	-113,000 Reduced 19.62%	463,000 $3.08 Million
Q1 2021 May 18, 2021	SELL	$9.1 - $19.57 $9.89 Million - $21.3 Million	-1,086,500 Reduced 65.35%	576,000 $5.33 Million
Q4 2020 Feb 12, 2021	SELL	$12.02 - $24.71 $830,582 - $1.71 Million	-69,100 Reduced 3.99%	1,662,500 $29.9 Million
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $4.85 Million - $16.2 Million	1,141,600 Added 193.49%	1,731,600 $24.6 Million

Q2 2020 Aug 14, 2020	BUY	$0.78 - $5.1 $460,200 - $3.01 Million	590,000 New	590,000 $2.96 Million

8.48M

798K

39.2K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $96.2M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.